← 返回

绘制过继性细胞治疗应答和耐药过程中 T 细胞状态的演变

英文原题:Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.

查看英文原题

Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.

PubMed 2021/11/09(内容时间) Cell Rep Q1 · IF 7.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

为了阐明T细胞消除白血病的机制,我们研究了供者淋巴细胞输注(DLI),这是一种已确立的用于复发性白血病的免疫治疗方法。我们通过整合来自94,517个骨髓来源的单T细胞转录组的纵向、多模态数据,以及来自接受DLI患者的染色质可及性和单T细胞受体测序,来建模T细胞动力学。我们发现,有应答的肿瘤其特征是在DLI前富集晚期分化的T细胞,治疗后早期分化的T细胞快速且持久扩增,分别与“终末”和“前体”耗竭亚群高度相似。相反,耐药的特征是异质性T细胞功能障碍。出乎意料的是,有应答者中的早期分化T细胞主要来源于已存在和新出现的、被招募到白血病微环境中的克隆型,而非输注物。我们的工作为分析过继细胞治疗之外场景的纵向单细胞图谱提供了一个范式,并引入了Symphony,一种推断T细胞亚群背后调控回路的贝叶斯方法,与跨癌症的耗竭拮抗剂具有广泛相关性。

展开英文摘要原文

To elucidate mechanisms by which T cells eliminate leukemia, we study donor lymphocyte infusion (DLI), an established immunotherapy for relapsed leukemia.

We model T cell dynamics by integrating longitudinal, multimodal data from 94,517 bone marrow-derived single T cell transcriptomes in addition to chromatin accessibility and single T cell receptor sequencing from patients undergoing DLI.

We find that responsive tumors are defined by enrichment of late-differentiated T cells before DLI and rapid, durable expansion of early differentiated T cells after treatment, highly similar to "terminal" and "precursor" exhausted subsets, respectively. Resistance, in contrast, is defined by heterogeneous T cell dysfunction. Surprisingly, early differentiated T cells in responders mainly originate from pre-existing and novel clonotypes recruited to the leukemic microenvironment, rather than the infusion.

Our work provides a paradigm for analyzing longitudinal single-cell profiling of scenarios beyond adoptive cell therapy and introduces Symphony, a Bayesian approach to infer regulatory circuitry underlying T cell subsets, with broad relevance to exhaustion antagonists across cancers.

论文信息

作者
Bachireddy P、Azizi E、Burdziak C、Nguyen VN、Ennis CS、Maurer K、Park CY、Choo ZN
第一作者单位
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Department of Hematopoietic Biology & Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research, Austin, TX 78701, USA. Electronic address: pbachireddy@mdanderson.org.United States
通讯作者单位
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: cwu@partners.org.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Cell reports2021 Nov 9
原文标识
PubMed 34758319 · DOI 10.1016/j.celrep.2021.109992